Expression of MHC class II, but not MHC class I, confers responsiveness to anti-PD-1 therapy in colon cancer and B and T cell lymphoma models [56] via cytotoxic CD4 T cells. This evidence concerns the gene CD4 and malignant colon neoplasm.